The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 13, 2024
View Complete Issue         Table of Contents 2019 
Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
May 13, 2024 (Issue: 1702)
Eflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent,...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Eflornithine (Iwilfin) for High-Risk Neuroblastoma (online only)
Article code: 1702f
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.